- Home
- BYSI vs AIFA Comparison
BYSI vs AIFA Comparison
Compare BYSI & AIFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYSI | AIFA |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 27.2M |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BYSI | AIFA |
|---|---|---|
| Price | $0.53 | $4.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 279.0K | ★ 387.2K |
| Earning Date | 11-11-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,655,039.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 20.50 |
| 52 Week Low | $0.53 | $1.52 |
| 52 Week High | $2.44 | $8.93 |
Technical Indicators
Market Signals| Indicator | BYSI | AIFA |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 45.06 |
| Support Level | N/A | $2.80 |
| Resistance Level | $0.80 | $8.93 |
| Average True Range (ATR) | 0.08 | 0.78 |
| MACD | -0.02 | -0.28 |
| Stochastic Oscillator | 3.10 | 4.96 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
About AIFA All In FutureTech Alliance Inc. Common Stock
All In FutureTech Alliance Inc operates an AI-focused digital infrastructure platform. Its activities include opportunities in AI infrastructure, silicon photonics-enabled computing, fiber-optic network transmission, digital infrastructure services, and technology-related initiatives. The company is also developing the AIFA platform, which is intended to combine AI computing capacity, fiber-optic network infrastructure, AI education, and AI-related applications.